BSECompany Update2d ago · 30 Jul 2026, 10:11 am
Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs
Wanbury Ltd · 524212
✦ AI Summary▲ PositiveRegulatory
Wanbury Ltd received 'No DMF deficiency letter' from USFDA for multiple ANDAs, indicating full compliance with regulatory requirements.
Analysis Scores
Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Wanbury Ltd - 524212 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Attachments (1)
📄pdf
Download →
eab49da1-48a6-4055-afd6-8bfa22483c14.pdf
View document text
30th July, 2026
BSE Limited National Stock Exchange of India Ltd,
PJ. Towers, Exchange Plaza,
Dalal Street Bandra Kurla Complex,
Mumbai- 400 001. Bandra (East), Mumbai - 400 051.
Script Code: 524212 Script Code: WANBURY
Dear Sir/Madam
Sub.: Fully Compliant - No DMF deficiency letter received from the office of USFDA for
multiple ANDAs
As per Regulation 30 of SEBI LODR, Wanbury Limited recently received “No DMF
deficiency letter” from the office of USFDA (US Food and Drug Administration) for multiple
ANDAs (Abbreviated New Drug Applications) with Metformin HCl API source of Wanbury
for different formulations.
As previously informed, Wanbury expanded business opportunities in South Korea for one
more API by filing the DMF. Wanbury is committed for supply of best APIs to the new
market for well-being of human being.
This is for your information and record.
Thanking you.
Yours faithfully,
For Wanbury Ltd
Jitendra J. Gandhi
Company Secretary